menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Prurigo Nodularis: Recent Advancements in Addressing Unmet Needs

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    Two therapies that were recently studied for the treatment of a chronic and debilitating skin disease, called prurigo nodularis, have shown promising results, including a reduction in itch. Read more on the promising results from the Phase 3 trial of nemolizumab, along with the effectiveness of dupilumab, and the ongoing research into emerging therapies.

Facebook Comments

Recommended
Details
Comments
  • Overview

    Two therapies that were recently studied for the treatment of a chronic and debilitating skin disease, called prurigo nodularis, have shown promising results, including a reduction in itch. Read more on the promising results from the Phase 3 trial of nemolizumab, along with the effectiveness of dupilumab, and the ongoing research into emerging therapies.

Facebook Comments

Schedule22 May 2024